The AIDO-RNA Foundation Model, the largest of its kind with 1.6 billion parameters, significantly enhances speed and accuracy in RNA structure prediction and drug design.

GenBio AI is at the forefront of biological advancements with its AI-Driven Digital Organism (AIDO), which utilizes multiscale foundation models to simulate, predict, and program biological outcomes.

This innovative technology aims to transform drug discovery, enhance disease understanding, and personalize medicine by enabling rapid testing and insightful analysis.

GenBio AI's models are designed to interact with one another, solving up to 300 tasks simultaneously, which addresses the silo problem in biology and AI research.

The company collaborates with leading institutions such as Carnegie Mellon University and Stanford, with a global presence that includes labs in Palo Alto, Paris, and Abu Dhabi.

The development of AIDO involved a team of experts from these prestigious institutions, and their findings were presented at the 38th Annual NeurIPS conference.

Among the various models, the AIDO-Protein Foundation Model stands out for its computational efficiency, facilitating advanced exploration of proteins.

Additionally, the AIDO-DNA Foundation Model features 7 billion parameters and is trained on data from 796 species, pushing the boundaries of DNA language models.

The AIDO-Single Cell Model processes the entire human transcriptome, representing a significant milestone in single-cell analysis.

AIDO also aids in understanding complex diseases, allowing researchers to explore systemic interactions and discover new intervention pathways.

Looking ahead, potential developments of AIDO include deeper integration of foundational models to advance synthetic biology, environmental sustainability, and longevity research.

Dr. Le Song, Co-Founder and CTO of GenBio AI, envisions a future where interactive digital versions of biological systems enable safe experimentation and precise modifications.